<DOC>
	<DOCNO>NCT01591863</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability , pharmacokinetics fidaxomicin pediatric subject Clostridium difficile-associated diarrhea ( CDAD ) .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Fidaxomicin Pediatric Subjects With Clostridium Difficile-associated Diarrhea ( CDAD )</brief_title>
	<detailed_description />
	<mesh_term>Diarrhea</mesh_term>
	<criteria>Male female 6 month 17 year 11 month age , inclusive ; Female subject childbearing potential must use adequate contraception Diagnosed CDAD Concurrent use oral vancomycin metronidazole effective treatment CDAD Fulminant colitis History inflammatory bowel disease Pregnant breastfeed Need concurrent use Pglycoprotein inhibitor therapy</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Clostridium difficile-associated diarrhea</keyword>
	<keyword>CDAD</keyword>
	<keyword>Pediatric</keyword>
</DOC>